Unstable Angina: Multimedia

References

1. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. Aug 12 2008;52(7):523-7. [Medline].

2. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. Apr 4 2001;285(13):1711-8. [Medline].

3. Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. Nov 15 1999;84(10):1145-50. [Medline].

4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494-502. [Medline].

5. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. Jul 16 1992;327(3):141-5. [Medline].

6. GRACE, Global Registry of Acute Coronary Events. Available at http://www.outcomes-umassmed.org/grace/. Accessed March 30, 2009.

7. Lupón J, Valle V, Marrugat J, et al. Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. Dec 1999;34(7):1947-53. [Medline].

8. Scanlon PJ, Nemickas R, Moran JF, Talano JV, Amirparviz F, Pifarre R. Accelerated angina pectoris. Clinical, hemodynamic, arteriographic, and therapeutic experience in 85 patients. Circulation. Jan 1973;47(1):19-26. [Medline].

9. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. Dec 1995;26(7):1643-50. [Medline].

10. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. Jun 18 1998;338(25):1785-92. [Medline].

11. FRISC Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].

12. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].

13. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].

14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329-39. [Medline].

15. GUSTO Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med. Sep 12 1996;335(11):775-82. [Medline].

16. Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J. Mar 2000;21(5):371-81. [Medline].

17. Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA. Jan 19 2000;283(3):347-53. [Medline].

18. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. Mar 1985;5(3):609-16. [Medline].

19. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. Aug 16 2000;284(7):835-42. [Medline].

20. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. Oct 31 1996;335(18):1342-9. [Medline].

21. Asher CR, Topol EJ, Moliterno DJ. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. Am Heart J. Dec 1999;138(6 Pt 1):1073-81. [Medline].

22. Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: A statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation. Aug 29 2000;102(9):1069-73. [Medline].

23. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. Jul 1990;82(1):17-26. [Medline].

24. [Best Evidence] Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. Oct 3 2006;48(7):1319-25. [Medline].

25. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. Apr 1 1998;128(7):541-4. [Medline].

26. Bhatt DL, Houghtaling P, Harrington RA, et al. Black patients presenting with acute coronary syndromes have better outcomes due to less extent of disease. J Am Coll Cardiol. 1999;33(2):365A.

27. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. Oct 13 1993;270(14):1702-7. [Medline].

28. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. Apr 12 2007;356(15):1503-16. [Medline].

29. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. Apr 12 2007;356(15):1503-16. [Medline].

30. Braunwald E. Unstable angina. A classification. Circulation. Aug 1989;80(2):410-4. [Medline].

31. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. Sep 2000;36(3):970-1062. [Medline].

32. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. Sep 5 2000;102(10):1193-209. [Medline].

33. Braunwald E, Mark DB, Jones RH, et al. Agency for Health Care and Policy Research (AHCPR). Unstable Angina. In: Diagnosis and Management. US Department of Health and Human Services. Washington, DC; 1994.

34. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol. Apr 1991;17(5):1053-7. [Medline].

35. Butman SM, Olson HG, Butman LK. Early exercise testing after stabilization of unstable angina: correlation with coronary angiographic findings and subsequent cardiac events. Am Heart J. Jan 1986;111(1):11-8. [Medline].

36. Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE. Validated risk stratification model accurately predicts low risk in patients with unstable angina. J Am Coll Cardiol. Nov 15 2000;36(6):1803-8. [Medline].

37. Campeau L. Letter: Grading of angina pectoris. Circulation. Sep 1976;54(3):522-3. [Medline].

38. Cannon CP, McCabe CH, Stone PH, et al. Prospective validation of the Braunwald classification of unstable angina: results from the Thrombolysis in Myocardial Ischemia (TIMI) III registry. Circulation. 1995;95(92):1-19.

39. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. Jul 1997;30(1):133-40. [Medline].

40. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol. Sep 1 1985;56(7):403-6. [Medline].

41. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. Dec 2000;36(7):2028-35. [Medline].

42. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. Aug 14 1997;337(7):447-52. [Medline].

43. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. Jan 8 1994;308(6921):81-106. [Medline].

44. Das P, Moliterno DJ. Fractionating heparins and their clinical trial data--something for everyone. JAMA. Jul 7 2004;292(1):101-3. [Medline].

45. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. Sep 15 2005;353(11):1095-104. [Medline].

46. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. Jul 15 2004;117(2):73-81. [Medline].

47. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. Jun 12 1997;336(24):1689-96. [Medline].

48. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. Jul 11 1998;352(9122):87-92. [Medline].

49. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. Dec 16 2000;356(9247):2037-44. [Medline].

50. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. Apr 1985;71(4):699-708. [Medline].

51. Fowler NO. "Preinfarctional" angina. A need for an objective definition and for a controlled clinical trial of its management. Circulation. Nov 1971;44(5):755-8. [Medline].

52. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. Sep 10-16 2005;366(9489):914-20. [Medline].

53. Freeman MR, Chisholm RJ, Armstrong PW. Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease. Am J Cardiol. Dec 1 1988;62(17):1164-70. [Medline].

54. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. Circulation. Jul 1989;80(1):17-23. [Medline].

55. Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S29-34. [Medline].

56. Goldman L, Cook EF, Johnson PA, Brand DA, Rouan GW, Lee TH. Prediction of the need for intensive care in patients who come to the emergency departments with acute chest pain. N Engl J Med. Jun 6 1996;334(23):1498-504. [Medline].

57. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation. Mar 1988;77(3):526-34. [Medline].

58. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. May 8 1986;314(19):1214-9. [Medline].

59. Guadagnoli E, Landrum MB, Peterson EA, Gahart MT, Ryan TJ, McNeil BJ. Appropriateness of coronary angiography after myocardial infarction among Medicare beneficiaries. Managed care versus fee for service. N Engl J Med. Nov 16 2000;343(20):1460-6. [Medline].

60. Harrington RA. Platelet IIb/IIIa in Unstable Angina:. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. For the PURSUIT Investigators. 1998.

61. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. Nov 20 1999;354(9192):1757-62. [Medline].

62. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. Jul 1997;30(1):141-8. [Medline].

63. Hohnloser SH, Meinertz T, Klingenheben T, Sydow B, Just H. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group. Am J Cardiol. Jun 15 1991;67(16):1319-23. [Medline].

64. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. May 21 1998;338(21):1488-97. [Medline].

65. Kirk JD, Turnipseed S, Lewis WR, Amsterdam EA. Evaluation of chest pain in low-risk patients presenting to the emergency department: the role of immediate exercise testing. Ann Emerg Med. Jul 1998;32(1):1-7. [Medline].

66. Krone RJ, Greenberg H, Dwyer EM Jr, Kleiger RE, Boden WE. Long-term prognostic significance of ST segment depression during acute myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. J Am Coll Cardiol. Aug 1993;22(2):361-7. [Medline].

67. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. Jun 15 1990;112(12):897-903. [Medline].

68. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol. Jun 1989;13(7):1495-502. [Medline].

69. Larsson H, Areskog M, Areskog NH, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?. Int J Card Imaging. 1991;7(1):7-14. [Medline].

70. Levine HD. Subendocardial infarction in retrospect: pathologic, cardiographic, and ancillary features. Circulation. Oct 1985;72(4):790-800. [Medline].

71. Lewis WR, Amsterdam EA, Turnipseed S, Kirk JD. Immediate exercise testing of low risk patients with known coronary artery disease presenting to the emergency department with chest pain. J Am Coll Cardiol. Jun 1999;33(7):1843-7. [Medline].

72. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. Oct 19 2000;343(16):1139-47. [Medline].

73. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. Jul 15 1987;60(2):18A-25A. [Medline].

74. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation. May 11 1999;99(18):2371-7. [Medline].

75. [Best Evidence] Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. Jun 15 2005;293(23):2908-17. [Medline].

76. [Best Evidence] Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. Jun 15 2005;293(23):2908-17. [Medline].

77. Moliterno D, Sapp S, Topol E. The paradoxical effect of thrombolytic therapy for unstable angina: meta-analysis. J Am Coll Cardiol. 1994;23:288A.

78. Moliterno D, Sgarbossa E, Armstrong P, et al. A major dichotomy in unstable angina outcome: ST depression vs. T-wave inversion--GUSTO II results. J Am Coll Cardiol. 1996;27:182A.

79. Moliterno DJ, Aguirre FV, Cannon CP, et al. The global unstable angina registry and treatment evaluation. Circulation. 1996;1:94.

80. Moliterno DJ, Asher CA, Califf RM, et al. Less myocardial but more cerebral ischemic events in African Americans than Caucasians with acute coronary syndromes: tesults from GUSTO-II. J Am Coll Cardiol. 1997;29:131A.

81. Moliterno DJ, Topol EJ. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. Am Heart J. Nov 2000;140(5):722-6. [Medline].

82. Moliterno DJ, Topol EJ. Meta-analysis of platelet GP IIb/IIIa antagonist randomized clinical trials: consistent, durable, salutary effects [abstract]. Circulation. 1997;96:I-475.

83. Moliterno DJ, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In: Lincoff A, Topol E, eds. Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa,. NJ: Humana; 1999:201-27.

84. Nichol G, Walls R, Goldman L, et al. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. Dec 1 1997;127(11):996-1005. [Medline].

85. Nichol G, Walls R, Goldman L, et al. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. Dec 1 1997;127(11):996-1005. [Medline].

86. NINDS. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis. National Institute of Neurological Disorders and Stroke. J Neurol Sci. Mar 1995;129(1):76-7. [Medline].

87. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet. Feb 6 1999;353(9151):429-38. [Medline].

88. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. Oct 31 1996;335(18):1333-41. [Medline].

89. Ondriasova E, Ondrias K, Stasko A, Nosal R, Csollei J. Comparison of the potency of five potential beta-adrenoceptor blocking drugs and eight calcium channel blockers to inhibit platelet aggregation and to perturb liposomal membranes prepared from platelet lipids. Physiol Res. 1992;41(4):267-72. [Medline].

90. Parker FB Jr, Neville JF Jr, Hanson EL, Webb WR. Retrograde and antegrade pressures and flows in preinfarction syndrome. Circulation. Aug 1974;50(2 Suppl):II122-6. [Medline].

91. Pearlman JD, Gertz ZM, Wu Y, Simons M, Post MJ. Serial motion assessment by reference tracking (SMART): application to detection of local functional impact of chronic myocardial ischemia. J Comput Assist Tomogr. Jul-Aug 2001;25(4):558-62. [Medline].

92. Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation--preliminary study in pigs. Radiology. Mar 2000;214(3):801-7. [Medline].

93. Peterson ED. What Have We Learned from the CRUSADE Registry? Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the AHA and ACC Guidelines. Available at www.clintrialresults.org/Slides/Crusade%20what%20have%20we%20learned.ppt. Accessed Dec. 28, 2008.

94. Piegas LS, Flather M, Pogue J, et al. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. Am J Cardiol. Sep 2 1999;84(5A):7M-12M. [Medline].

95. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. Apr 20 2000;342(16):1163-70. [Medline].

96. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. May 17 1997;349(9063):1429-35. [Medline].

97. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. Oct 6 1990;336(8719):827-30. [Medline].

98. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation. Feb 1982;65(2):281-5. [Medline].

99. Scirica BM, Moliterno DJ, Every NR, et al. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. Dec 1999;138(6 Pt 1):1065-72. [Medline].

100. Selker HP, Beshansky JR, Griffith JL, et al. Use of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia. A multicenter, controlled clinical trial. Ann Intern Med. Dec 1 1998;129(11):845-55. [Medline].

101. Shaw LJ, Peterson ED, Kesler K, Hasselblad V, Califf RM. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol. Dec 15 1996;78(12):1327-37. [Medline].

102. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. Mar 3 1999;281(9):806-10. [Medline].

103. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation. Sep 15 1996;94(6):1291-7. [Medline].

104. Swahn E, Areskog M, Berglund U, Walfridsson H, Wallentin L. Predictive importance of clinical findings and a predischarge exercise test in patients with suspected unstable coronary artery disease. Am J Cardiol. Feb 1 1987;59(4):208-14. [Medline].

105. Tan WA, Ellis SG. Interventional cardiology. In: Marso SP, Griffin BP, Topol EJ, eds. Manual of Cardiovascular Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:722-43.

106. Tan WA, Moliterno DJ. Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives. Cleve Clin J Med. Nov-Dec 1999;66(10):615-8, 621-4, 627-8. [Medline].

107. Tan WA, Moliterno DJ. TIMI flow and surrogate end points: what you see is not always what you get. Am Heart J. Oct 1998;136(4 Pt 1):570-3. [Medline].

108. Taneva E, Bogdanova V, Shtereva N. Acute coronary syndrome, comorbidity, and mortality in geriatric patients. Ann N Y Acad Sci. Jun 2004;1019:106-10. [Medline].

109. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med. Jan 1997;29(1):116-25. [Medline].

110. Theroux P, Lidon RM. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol. Mar 1993;18(3):157-231. [Medline].

111. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. Oct 27 1988;319(17):1105-11. [Medline].

112. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. May 8 1999;353(9164):1547-57. [Medline].

113. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. Apr 7 1994;330(14):956-61. [Medline].

114. VAKIL RJ. PREINFARCTION SYNDROME--MANAGEMENT AND FOLLOW-UP. Am J Cardiol. Jul 1964;14:55-63. [Medline].

115. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. Jul 1 2000;356(9223):9-16. [Medline].

116. Wallis DE, Pope C, Littman WJ, Scanlon PJ. Safety and efficacy of esmolol for unstable angina pectoris. Am J Cardiol. Nov 15 1988;62(16):1033-7. [Medline].

117. Wilcox I, Freedman SB, Allman KC, et al. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. J Am Coll Cardiol. Sep 1991;18(3):677-83. [Medline].

118. WooD P. Acute and subacute coronary insufficiency. Br Med J. Jun 24 1961;1(5242):1779-82. [Medline].

119. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. Jan 13 2000;342(2):101-14. [Medline].

Further Reading

Keywords

unstable angina, myocardial infarction, acute coronary syndrome, preinfarction angina, intermediate coronary syndrome, accelerated angina, crescendo angina, chest pain, heart attack, coronary disease, hypertrophic obstructive cardiomyopathy, HOCM, microvascular disease, atherosclerotic plaque, atherosclerosis, plaque rupture, cholesterol, new-onset angina, accelerating angina, rest angina, early postinfarct angina, early postrevascularization angina, non–Q-wave myocardial infarction, non–Q-wave MI, NQMI, non-STEMI, NSTEMI, UA, MI, ACS

Contributor Information and Disclosures

Author

Walter A Tan, MD, MS, Associate Professor of Medicine, Clinical Associate Professor of Surgery, Director of Stroke Interventions, Associate Director of Cardiac Catheterization, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University
Walter A Tan, MD, MS is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American Heart Association, American Stroke Association, National Stroke Association, Society for Vascular Medicine and Biology, and Society of Interventional Radiology
Disclosure: Novartis Honoraria Other

Coauthor(s)

David J Moliterno, MD, Professor of Medicine, Jefferson Morris Gill Professor of Cardiology, Chief, Division of Cardiovascular Medicine, University of Kentucky; Vice Chairman of Internal Medicine, Chandler Medical Center; Medical Director, Gill Heart Institute
David J Moliterno, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, Association of Professors of Cardiology, and European Society of Cardiology
Disclosure: Nothing to disclose.

Steven James Filby, MD, Fellow in Interventional Cardiology, The Cleveland Clinic Foundation
Disclosure: Nothing to disclose.

Medical Editor

Justin D Pearlman, MD, PhD, ME, MA, Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Marschall S Runge, MD, PhD, Charles and Anne Sanders Distinguished Professor of Medicine, Chairman, Department of Medicine, Vice Dean for Clinical Affairs, University of North Carolina at Chapel Hill School of Medicine
Marschall S Runge, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society for Investigative Pathology, Association of American Physicians, Association of Professors of Cardiology, Association of Professors of Medicine, Southern Society for Clinical Investigation, and Texas Medical Association
Disclosure: Pfizer Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Orthoclinica Diagnostica Consulting fee Consulting

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Eric H Yang, MD, Assistant Professor of Medicine, Director of Coronary Care Unit, University of North Carolina at Chapel Hill School of Medicine
Eric H Yang, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Up to Date Royalty Review panel membership